

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

MSN Labs launches Favilow (Faripiravir) 800mg tablets to fight COVID-19

28 April 2021 | News

The higher strength Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies



In order to address the shortage of the antiviral drug, Favipiravir to treat mild and moderate COVID-19 flu, Hyderabad based [MSN Laboratories](#), have announced the launch of its branded generic, Favilow 800 mg.

The higher strength Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies. The field team of MSN Labs is also helping out with free home delivery in over 170 cities in coordination with local retail chemists for patient convenience.

Dr MSN Reddy, CMD – MSN Group said, “In the light of increasing COVID-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation’s efforts in overcoming the COVID crisis.”

MSN had launched the world’s most [affordable branded generic of Favipiravir](#), Favilow, in August last year, in the strengths of 200 and 400 mg. MSN claims the higher strength will improve patient compliance and experience by effectively reducing the number of tablets a patient requires per day.

The launch would also address the shortages and issues faced by the patients in procuring the [COVID-19 drug](#).

The higher strength of Favipiravir 800 mg from MSN has been approved by the [Drug Controller General of India \(DCGI\)](#). MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW 800 mg in its in-house R&D and manufacturing units.